594 related articles for article (PubMed ID: 29167212)
1. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.
Wild SH; Walker JJ; Morling JR; McAllister DA; Colhoun HM; Farran B; McGurnaghan S; McCrimmon R; Read SH; Sattar N; Byrne CD;
Diabetes Care; 2018 Feb; 41(2):341-347. PubMed ID: 29167212
[TBL] [Abstract][Full Text] [Related]
2. Economic and Clinical Burden of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes in the U.S.
Younossi ZM; Tampi RP; Racila A; Qiu Y; Burns L; Younossi I; Nader F
Diabetes Care; 2020 Feb; 43(2):283-289. PubMed ID: 31658974
[TBL] [Abstract][Full Text] [Related]
3. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease and alcoholic liver disease: multicenter survey.
Tokushige K; Hyogo H; Nakajima T; Ono M; Kawaguchi T; Honda K; Eguchi Y; Nozaki Y; Kawanaka M; Tanaka S; Imajo K; Sumida Y; Kamada Y; Fujii H; Suzuki Y; Kogiso T; Karino Y; Munekage K; Kuromatsu R; Oeda S; Yanase M; Mori K; Ogawa Y; Seko Y; Takehara T; Itoh Y; Nakajima A; Kanemasa K; Nishino K; Masaki N; Takahashi H; Seike M; Torimura T; Saibara T; Toyota J; Chayama K; Hashimoto E
J Gastroenterol; 2016 Jun; 51(6):586-96. PubMed ID: 26456168
[TBL] [Abstract][Full Text] [Related]
4. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease.
Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK
Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360
[TBL] [Abstract][Full Text] [Related]
5. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
[TBL] [Abstract][Full Text] [Related]
6. Type 2 diabetes and risk of hospital admission or death for chronic liver diseases.
Wild SH; Morling JR; McAllister DA; Kerssens J; Fischbacher C; Parkes J; Roderick PJ; Sattar N; Byrne CD; ;
J Hepatol; 2016 Jun; 64(6):1358-64. PubMed ID: 26812073
[TBL] [Abstract][Full Text] [Related]
7. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
8. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Ahn SY; Kim SB; Song IH
Can J Gastroenterol Hepatol; 2020; 2020():4873875. PubMed ID: 32566546
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.
Akuta N; Kawamura Y; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
BMC Gastroenterol; 2018 Nov; 18(1):165. PubMed ID: 30400829
[TBL] [Abstract][Full Text] [Related]
10. Hospital admission with non-alcoholic fatty liver disease is associated with increased all-cause mortality independent of cardiovascular risk factors.
Mann JP; Carter P; Armstrong MJ; Abdelaziz HK; Uppal H; Patel B; Chandran S; More R; Newsome PN; Potluri R
PLoS One; 2020; 15(10):e0241357. PubMed ID: 33108366
[TBL] [Abstract][Full Text] [Related]
11. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis.
Morrison AE; Zaccardi F; Khunti K; Davies MJ
Liver Int; 2019 Mar; 39(3):557-567. PubMed ID: 30358050
[TBL] [Abstract][Full Text] [Related]
12. Non-alcoholic fatty liver disease is associated with greater risk of 30-day hospital readmission in the United States (U.S.).
Paik JM; Eberly KE; Kabbara K; Harring M; Younossi Y; Henry L; Verma M; Younossi ZM
Ann Hepatol; 2023; 28(4):101108. PubMed ID: 37088421
[TBL] [Abstract][Full Text] [Related]
13. Association Between Diabetes Mellitus and All-Cause and Cardiovascular Mortality Among Individuals With Ultrasound-Defined Non-Alcoholic Fatty Liver Disease.
Wu W; Xiang J; Chen X
Front Endocrinol (Lausanne); 2021; 12():773342. PubMed ID: 34992579
[TBL] [Abstract][Full Text] [Related]
14. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification.
Ioannou GN; Green P; Kerr KF; Berry K
J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929
[TBL] [Abstract][Full Text] [Related]
15. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study.
Hong TP; Gow PJ; Fink M; Dev A; Roberts SK; Nicoll A; Lubel JS; Kronborg I; Arachchi N; Ryan M; Kemp WW; Knight V; Sundararajan V; Desmond P; Thompson AJ; Bell SJ
Med J Aust; 2018 Oct; 209(8):348-354. PubMed ID: 30309301
[TBL] [Abstract][Full Text] [Related]
16. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis.
Bengtsson B; Stål P; Wahlin S; Björkström NK; Hagström H
Liver Int; 2019 Jun; 39(6):1098-1108. PubMed ID: 30829446
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic Fatty Liver Disease Associates With Increased Overall Mortality and Death From Cancer, Cardiovascular Disease, and Liver Disease in Women but Not Men.
Hwang YC; Ahn HY; Park SW; Park CY
Clin Gastroenterol Hepatol; 2018 Jul; 16(7):1131-1137.e5. PubMed ID: 29158157
[TBL] [Abstract][Full Text] [Related]
18. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.
Simon TG; Roelstraete B; Khalili H; Hagström H; Ludvigsson JF
Gut; 2021 Jul; 70(7):1375-1382. PubMed ID: 33037056
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.
Tateishi R; Okanoue T; Fujiwara N; Okita K; Kiyosawa K; Omata M; Kumada H; Hayashi N; Koike K
J Gastroenterol; 2015 Mar; 50(3):350-60. PubMed ID: 24929638
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data.
Loomba R; Wong R; Fraysse J; Shreay S; Li S; Harrison S; Gordon SC
Aliment Pharmacol Ther; 2020 Jun; 51(11):1149-1159. PubMed ID: 32372515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
